The obesity drug market is at a critical juncture after a string of lackluster results and a significant slowdown in new startup launches. Once touted as the biggest pharmaceutical market of all time, investors are increasingly souring on the sector.
Eli Lilly’s Zepbound was once a promising example of an obesity medication, but recent developments have failed to live up to expectations. The company’s efforts to expand its use of the drug and increase sales have been met with disappointing results.
The decline in investor enthusiasm has had a ripple effect throughout the industry, leading to reduced funding for new startups focused on obesity treatments. This shift marks a significant turning point for the market, which was once heavily invested in finding innovative solutions to help millions of people struggling with weight-related health issues.
Source: https://endpoints.news/obesity-drug-market-hits-turning-point-after-lackluster-results-and-lull-in-startups